This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Guglielmo Nasti, MD; Giorgio Zanette, MD; Sandro Inchiostro, MD; Valter Donadon, MD; Umberto Tirelli, MD
Aviano, Italy

Arch Intern Med. 1995;155(6):645-646.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

It is known that pentamidine can cause severe pancreatic toxicity in patients with the acquired immunodeficiency syndrome.¹ The most frequent and severe adverse event is hypoglycemia that occurs in 6% to 35% of patients assuming pentamidine with a higher incidence in those who are seropositive for the human immunodeficiency virus.² Occasionally, hyperglycemia and acute pancreatitis have also been reported.³ Diabetes mellitus is a much less commonly recognized complication. Only a few cases have been reported in the literature and the real incidence of diabetes mellitus developing after intravenous pentamidine therapy is unknown.^2,4,5

We describe a case of transient diabetes mellitus presenting after pentamidine therapy in a patient with the acquired immunodeficiency syndrome.

Report of a Case.

A 29-year-old man who was an intravenous drug user became infected with the human immunodeficiency virus in 1986. He was admitted to our hospital with a diagnosis of Pneumocystis carinii . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?